Core Global Portfolio Drives Takeda Despite Pockets Of Weakness
Entyvio Solid But Hematology More Challenging
Japanese firm raises full-year forecast for core operating profit on continued growth for global brands, despite US recall and hematology pressures.
You may also be interested in...
Public Company Edition: Direct Biologics, YishengBio and Estrella Biopharma will go public by merging with special purpose acquisition corporations. Also, Vir lands a government contract worth up to $1bn, Idorsia raises CHF164m ($167.4m) in a real estate deal and Adamis reviews alternatives.
In a continued effort to pay down its debt pile from the acquisition of Shire, Takeda is to offload around 30 selected OTC and Rx products in certain Middle East and other emerging markets to private Swiss group Acino.
In this week's podcast edition of Five Must-Know Things: a preview of the CTAD Alzheimer’s meeting; US myeloma drug withdrawal puts pressure on GSK; UniQure/CSL's gene therapy sets new US price record; new leadership at Teva; and Merck’s Frazier cautions against profit maximization.